Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by Wino115on Sep 02, 2022 4:08pm
281 Views
Post# 34939157

THTX Crowdsource Research: TH1902 Status, Derisk needs

THTX Crowdsource Research: TH1902 Status, Derisk needsI've been building a spreadsheet around the parts of the PDC that need to work in order for it to be a success and what data we know around the issues. Given more will be learned before year end and the 1A data dump in 1Q23 (according to CEO), the more derisking of the elements, the more the share should start to reflect this. Similarly, if data confirms or is trending negative, it's going to be a drag on the valuation. We are where we are because there's only been a small amount of safety data given and just hints around efficacy. That should change before year end.

I'm just trying to categorize the various POC/MOA issues and if anything either proves it or allows a strong inference that it's happening.  Not being a scientist, I'm sure I"ve confused some issues and missed some too.  I'm happy to share it (PDF or XLS) in the link below that should be accessible to all.

If anyone has better ideas, corrections, ommissions or different views that can be substantiated, or correcting some of my incorrect thoughts, I will update and try to keep this up to date as we hopefully see more de-risking over the next few months. More greens are the only way the share will be going up in my view. There wasn't enough in the 1A release to really answer any of the derisking questions, it just provided the dose as it was supposed to and some interesting hints, but none which were investable. More patients under a larger trial will obviously provide what's needed to answer or provide a better probability we can infer success on some of these issues.  

Like I said, additions, substractions, corrections are all welcomed.  I'm sure I've missed or misstated some things, but it's a start since we have 3 months.  I also think we should use both officially released data and the unique experiences from anywhere else they are found to handicapp these issues. Those other data points are highly useful and supportable. Let me know if you believe something should be changed and updated. RIght now, there's only a few hints of green in safety issues and most of it is, as we know, not known one way or the other --not de-risked. 

PDF Checklist:   
PDF Checklist

XLS Checklist:
XLS Checklist

<< Previous
Bullboard Posts
Next >>